Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRORADGLIO: Pulsed Reduced Dose Radiotherapy in Upfront Glioblastoma
NCT04747145Phase 2Active, not recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Jun 2021
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Medical College of Wisconsin. Primary endpoint: Progression-free survival at 6 months. Started Jun 2021; status: active, not recruiting.
Beyond the preview
Go deeper on NCT04747145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04747145.